跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 369,850 条关于
“Luminal A (HR+/HER2-) Breast Cancer”
全部
369,850
临床试验
316,153
药物
7,984
机构
4,940
资讯
40,773
2个月前
Judicial Delay in Landmark Ribociclib Access Case: Petitioner Dies as Kerala High Court Lists Matter 57 Times Without Final Hearing
去年
Adjuvant Ribociclib Approved for HR+/HER2- Early Breast Cancer, Offering New Hope for High-Risk Patients
4个月前
MammaPrint Genomic Profiling Predicts Anthracycline Benefit in HR+HER2- Early Breast Cancer, Guiding NCCN Guideline Update
8个月前
NCCN Guidelines Now Recognize MammaPrint Testing to Guide Anthracycline Use in HR+/HER2- Breast Cancer
去年
Pelareorep Plus Paclitaxel Shows Survival Benefit in HR+/HER2- Breast Cancer
去年
FITWISE Trial Explores Tirzepatide's Impact on Weight Loss and Safety in Early-Stage HR+/HER2- Breast Cancer
去年
Genentech's Inavolisib Receives FDA Approval for Advanced HR+, HER2- Breast Cancer
2年前
De-escalated Therapy Shows Excellent Survival in HR+/HER2+ Breast Cancer
9个月前
MHRA Approves Inavolisib for Advanced HR-Positive, HER2-Negative Breast Cancer
去年
Sacituzumab Govitecan Shows Promise in Heavily Pretreated HR+/HER2- Breast Cancer Patients
第 1 页，共 4078 页
上一页
下一页
